{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:37:48Z","timestamp":1699922268398},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Temozolomide (TMZ) has been used as a first-line therapy against lower-grade gliomas (LGGs) combined with other chemotherapy drugs. However, there has been no reliable index predicting TMZ response of patients with LGGs. In this study, we aim to investigate the relationship between gene expressions and the prognosis of TMZ therapy in LGGs. We integrated transcriptome and clinical data of 171 LGGs from the Chinese Glioma Genome Atlas (CGGA). Consensus LASSO Cox regression was used to identify 14 key genes related to different clinical outcomes under TMZ chemotherapy. We constructed and evaluated a risk score based on the 14 genes. Patients with LGGs of lower risk scores (low-risk group) generally had better survival than those LGGs of higher risk scores (high-risk group), which is independent of clinicopathological factors. High-risk patients showed activation of innate and humoral-type immunity. The prognostic contribution of the risk score was validated in an independent validation cohort of 65 patients. Besides, combined with three independent predictors (grade, IDH1 mutation status, and chr1p19q co-deletion status), we further developed a nomogram to predict the benefit of TMZ treatment in LGGs. Our results indicate that a transcriptome-based index can optimize the treatment strategy for patients with LGGs under TMZ therapy.<\/jats:p>","DOI":"10.1007\/s12672-023-00818-9","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T15:01:42Z","timestamp":1699887702000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy"],"prefix":"10.1007","volume":"14","author":[{"given":"Yanzhi","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyue","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"issue":"8","key":"818_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231\u201351.","journal-title":"Neuro Oncol"},{"issue":"4","key":"818_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1634\/theoncologist.2013-0345","volume":"19","author":"DA Forst","year":"2014","unstructured":"Forst DA, et al. Low-grade gliomas. Oncologist. 2014;19(4):403\u201313.","journal-title":"Oncologist"},{"issue":"26","key":"818_CR3","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Brat DJ, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"818_CR4","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2021.11.FOCUS21587","volume":"52","author":"AF Haddad","year":"2022","unstructured":"Haddad AF, et al. The immunology of low-grade gliomas. Neurosurg Focus. 2022;52(2):E2.","journal-title":"Neurosurg Focus"},{"issue":"29","key":"818_CR5","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1200\/JCO.19.03327","volume":"38","author":"IK Mellinghoff","year":"2020","unstructured":"Mellinghoff IK, et al. Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma. J Clin Oncol. 2020;38(29):3398\u2013406.","journal-title":"J Clin Oncol"},{"issue":"6","key":"818_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1097\/WCO.0000000000000390","volume":"29","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF, Hegi ME, Baumert BG. Current management of low-grade gliomas. Curr Opin Neurol. 2016;29(6):782\u20138.","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"818_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS, et al. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021;1876(2): 188616.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"818_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cam4.2686","volume":"9","author":"SGR McDuff","year":"2020","unstructured":"McDuff SGR, et al. Radiation and chemotherapy for high-risk lower grade gliomas: choosing between temozolomide and PCV. Cancer Med. 2020;9(1):3\u201311.","journal-title":"Cancer Med"},{"issue":"6167","key":"818_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.1239947","volume":"343","author":"BE Johnson","year":"2014","unstructured":"Johnson BE, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2014;343(6167):189\u201393.","journal-title":"Science"},{"issue":"11","key":"818_CR10","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/neuonc\/noab081","volume":"23","author":"Y Yu","year":"2021","unstructured":"Yu Y, et al. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021;23(11):1872\u201384.","journal-title":"Neuro Oncol"},{"issue":"2","key":"818_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/cns.13464","volume":"27","author":"G Li","year":"2021","unstructured":"Li G, et al. A novel DNA repair-related nomogram predicts survival in low-grade gliomas. CNS Neurosci Ther. 2021;27(2):186\u201395.","journal-title":"CNS Neurosci Ther"},{"issue":"29","key":"818_CR12","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell EH, et al. Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase iii trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol. 2020;38(29):3407\u201317.","journal-title":"J Clin Oncol"},{"issue":"10","key":"818_CR13","doi-asserted-by":"publisher","first-page":"7327","DOI":"10.3390\/curroncol29100576","volume":"29","author":"M Deacu","year":"2022","unstructured":"Deacu M, et al. Prognostic factors of low-grade gliomas in adults. Curr Oncol. 2022;29(10):7327\u201342.","journal-title":"Curr Oncol"},{"key":"818_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3389\/fonc.2020.00669","volume":"10","author":"HQ Cai","year":"2020","unstructured":"Cai HQ, et al. Identifying predictive gene expression and signature related to temozolomide sensitivity of glioblastomas. Front Oncol. 2020;10:669.","journal-title":"Front Oncol"},{"key":"818_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainres.2013.05.021","volume":"1521","author":"L Xia","year":"2013","unstructured":"Xia L, et al. PAX3 is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Brain Res. 2013;1521:68\u201378.","journal-title":"Brain Res"},{"key":"818_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fnmol.2018.00187","volume":"11","author":"H Zhu","year":"2018","unstructured":"Zhu H, et al. Transcriptional repression of p53 by PAX3 contributes to gliomagenesis and differentiation of glioma stem cells. Front Mol Neurosci. 2018;11:187.","journal-title":"Front Mol Neurosci"},{"issue":"4","key":"818_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.7150\/ijbs.57168","volume":"17","author":"X Wang","year":"2021","unstructured":"Wang X, et al. Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p\/GRB14\/PDGFR\u03b1 pathway as a key regulatory mechanism in glioblastoma progression and radioresistance: functional validation and clinical theranostic significance. Int J Biol Sci. 2021;17(4):1061\u201378.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"818_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/cns.13382","volume":"26","author":"R Huang","year":"2020","unstructured":"Huang R, et al. RGS16 promotes glioma progression and serves as a prognostic factor. CNS Neurosci Ther. 2020;26(8):791\u2013803.","journal-title":"CNS Neurosci Ther"},{"key":"818_CR19","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fgene.2019.00909","volume":"10","author":"Z Qiao","year":"2019","unstructured":"Qiao Z, et al. Mutations in KIAA1109, CACNA1C, BSN, AKAP13, CELSR2, and HELZ2 Are associated with the prognosis in endometrial cancer. Front Genet. 2019;10:909.","journal-title":"Front Genet"},{"issue":"1","key":"818_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12032-021-01603-w","volume":"39","author":"H Dai","year":"2021","unstructured":"Dai H, et al. HELZ2 promotes K63-linked polyubiquitination of c-Myc to induce retinoblastoma tumorigenesis. Med Oncol. 2021;39(1):11.","journal-title":"Med Oncol"},{"key":"818_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153587","volume":"225","author":"Q Xing","year":"2021","unstructured":"Xing Q, et al. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence. Pathol Res Pract. 2021;225: 153587.","journal-title":"Pathol Res Pract"},{"issue":"3","key":"818_CR22","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/path.5997","volume":"258","author":"JT Kim","year":"2022","unstructured":"Kim JT, et al. Adrenomedullin2 stimulates progression of thyroid cancer in mice and humans under nutrient excess conditions. J Pathol. 2022;258(3):264\u201377.","journal-title":"J Pathol"},{"issue":"2","key":"818_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10549-022-06687-0","volume":"195","author":"L Kong","year":"2022","unstructured":"Kong L, et al. Intermedin (adrenomedullin 2) promotes breast cancer metastasis via Src\/c-Myc-mediated ribosome production and protein translation. Breast Cancer Res Treat. 2022;195(2):91\u2013103.","journal-title":"Breast Cancer Res Treat"},{"key":"818_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04609-1","author":"X He","year":"2023","unstructured":"He X, et al. Machine learning-based immune prognostic model and ceRNA network construction for lung adenocarcinoma. J Cancer Res Clin Oncol. 2023. https:\/\/doi.org\/10.1007\/s00432-023-04609-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"818_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1006\/bbrc.2000.4191","volume":"280","author":"J Bylund","year":"2001","unstructured":"Bylund J, Bylund M, Oliw EH. cDna cloning and expression of CYP4F12, a novel human cytochrome P450. Biochem Biophys Res Commun. 2001;280(3):892\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"818_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.667884","volume":"11","author":"X Zhu","year":"2021","unstructured":"Zhu X, et al. Novel biomarker genes for prognosis of survival and treatment of glioma. Front Oncol. 2021;11: 667884.","journal-title":"Front Oncol"},{"issue":"3","key":"818_CR27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1200\/JCO.2000.18.3.636","volume":"18","author":"JS Smith","year":"2000","unstructured":"Smith JS, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18(3):636\u201345.","journal-title":"J Clin Oncol"},{"issue":"4","key":"818_CR28","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1200\/JCO.1997.15.4.1294","volume":"15","author":"C Leighton","year":"1997","unstructured":"Leighton C, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15(4):1294\u2013301.","journal-title":"J Clin Oncol"},{"issue":"6","key":"818_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130872","volume":"10","author":"MY Li","year":"2015","unstructured":"Li MY, et al. Isocitrate dehydrogenase 1 gene mutation is associated with prognosis in clinical low-grade gliomas. PLoS ONE. 2015;10(6): e0130872.","journal-title":"PLoS ONE"},{"issue":"12 Suppl","key":"818_CR30","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1586\/14737140.7.12s.S15","volume":"7","author":"I Duran","year":"2007","unstructured":"Duran I, Raizer JJ. Low-grade gliomas: management issues. Expert Rev Anticancer Ther. 2007;7(12 Suppl):S15-21.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"5","key":"818_CR31","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/neuonc\/noz191","volume":"22","author":"H Gittleman","year":"2020","unstructured":"Gittleman H, Sloan AE, Barnholtz-Sloan JS. An independently validated survival nomogram for lower-grade glioma. Neuro Oncol. 2020;22(5):665\u201374.","journal-title":"Neuro Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00818-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-023-00818-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00818-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T15:20:27Z","timestamp":1699888827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-023-00818-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["818"],"URL":"https:\/\/doi.org\/10.1007\/s12672-023-00818-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"24 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}